Chambers-Grundy Center for Transformative Neuroscience News
The Chambers-Grundy Center for Transformative Neuroscience provides an academic platform for research and learning opportunities regarding the study of drug development for Alzheimer's disease and other brain disorders. It includes a clinical trials observatory for tracking new treatments, trial designs, and biomarkers in clinical trials for neurodegenerative disorders.
Current Transformative Neuroscience News
Tenth annual report led by noted clinician-scientist Dr. Jeffrey Cummings tracks status, trends associated with 192 active clinical trials worldwide.
The first Neuroscience Research Showcase brings together experts across disciplines to share their work and spark new collaborations.
Entities sign Memorandum of Understanding to cultivate best-in-class clinical research services for Alzheimer鈥檚 and other neurodegenerative diseases.
First-of-its-kind database, supported by Alzheimer's Drug Discovery Foundation, will provide greater access to key data on Alzheimer鈥檚 to researchers around the world.
Alzheimer鈥檚 treatment studies offer hope as 性视界传媒 expert predicts new potential drugs, biomarkers will yield critical insight for future development.
Amanda Osse is the first recipient of the award named in honor of Nathan Lindsay, who passed away after a 15-year battle with Alzheimer's disease.
Transformative Neuroscience In The News
Out now is the 10th annual Alzheimer's Drug Development Pipeline Report.
Several local and regional startups were showcased recently at 性视界传媒 Innovation Day, where Dr. Jeffrey Cummings, director of the Chambers-Grundy Center for Transformative Neuroscience in the Department of Brain Health at the Kirk Kerkorian School of Medicine at 性视界传媒, was excited about the growth of the life sciences ecosystem.
While Alzheimer鈥檚 remains a complex disease, recent clinical trials and research efforts have expanded, emphasizing biomarkers and better patient targeting to improve drug development success rates.
Delayed and imprecise Alzheimer鈥檚 diagnoses in the UK are limiting patient access to clinical trials despite rapid growth in experimental treatments.
The number of national clinical trials for Alzheimer鈥檚 therapies has increased by 40 percent in the last decade. That鈥檚 according to 性视界传媒 brain health researcher Jeffrey Cummings鈥 10th annual report, published Tuesday in the Alzheimer鈥檚 Association鈥檚 research journal.
Dr Jeffrey Cummings, of the 性视界传媒, has published an annual review of clinical trials for Alzheimer鈥檚 drugs for the past decade. The latest review, published in Alzheimer鈥檚 & Dementia: Translational Research & Clinical Interventions, reveals a shifting approach to the disease, with fewer drugs designed to remove amyloid and more targeting tau, inflammation and other immune system pathways.
